Search

Displaying results 2521 - 2530 of 9697 in total
  1. Drug

    Lotrafiban

    go.drugbank.com/drugs/DB20872
    Experimental

    Lotrafiban has a monoisotopic molecular weight of 428.24 Da. … Lotrafiban is a small molecule drug. The usage of the INN stem '-fiban' in the name indicates that Lotrafiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist).

  2. Drug

    Tanogitran

    go.drugbank.com/drugs/DB21367
    Investigational

    Tanogitran has a monoisotopic molecular weight of 477.25 Da. … Tanogitran is a small molecule drug.

  3. Drug

    Masofaniten

    go.drugbank.com/drugs/DB21580
    Investigational

    Masofaniten has a monoisotopic molecular weight of 534.09 Da. … Masofaniten is a small molecule drug.

  4. Drug

    Pixavir marboxil

    go.drugbank.com/drugs/DB21589
    Experimental

    Pixavir marboxil has a monoisotopic molecular weight of 540.12 Da. … Pixavir marboxil is a small molecule drug. The usage of the INN stem '-xavir' in the name indicates that Pixavir marboxil is a influenza CAP-dependent endonuclease inhibitor.

  5. Drug

    Crelosidenib

    go.drugbank.com/drugs/DB21642
    Investigational

    Crelosidenib has a monoisotopic molecular weight of 504.28 Da. … Crelosidenib is a small molecule drug.

  6. Drug

    Rosabulin

    go.drugbank.com/drugs/DB20161
    Investigational

    Rosabulin has a monoisotopic molecular weight of 400.1 Da. … Rosabulin is a small molecule drug. Rosabulin is under investigation in clinical trial NCT00276913 (A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors).

  7. Drug

    Lunsotogene parvec

    go.drugbank.com/drugs/DB18278
    ApprovedInvestigational

    It is the first gene therapy to be approved under the Commissioner's National Priority Voucher (CNPV) pilot and represents one of the fastest BLA approvals in modern history, with a time between filing … [L56135,L56136] This landmark decision followed designations as a Regenerative Medicine Advanced Therapy (RMAT) and Fast Track, marking the first-ever gene therapy approved to restore a neurosensory function

  8. Drug

    Bulevirtide

    go.drugbank.com/drugs/DB15248
    ApprovedInvestigational

    [A226305] Bulevirtide, also known as Hepcludex, is a first-in-class entry inhibitor for the treatment of chronic Hepatitis D infection developed by MYR Pharmaceuticals, now part of Gilead. … potentially beneficial synergistic effects in treating chronic Hepatitis D, bulevirtide is also under investigation in clinical trial NCT03852433 (Phase 2b Study of Bulevirtide With [Peginterferon Alfa-2a

  9. Drug

    Tebapivat

    go.drugbank.com/drugs/DB19338
    Investigational

    Tebapivat is under investigation in clinical trial NCT05490446 (A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-risk Myelodysplastic Syndromes (LR-MDS)).

  10. Drug

    Aspartyl-alanyl-diketopiperazine

    go.drugbank.com/drugs/DB14940
    Investigational

    Aspartyl-alanyl-diketopiperazine is under investigation in clinical trial NCT03349645 (An Open Label Extension Study to Assess the Safety of Long-Term Treatment With Ampion for Severe OA of the Knee).